Cost-effectiveness analysis of multiple sclerosis treatment approaches

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21460%2F24%3A00371587" target="_blank" >RIV/68407700:21460/24:00371587 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1007/978-3-031-62520-6_9" target="_blank" >https://doi.org/10.1007/978-3-031-62520-6_9</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/978-3-031-62520-6_9" target="_blank" >10.1007/978-3-031-62520-6_9</a>

Result language
angličtina
Original language name
Cost-effectiveness analysis of multiple sclerosis treatment approaches
Original language description
Multiple sclerosis is associated with significant impacts on both the patient's quality of life and the healthcare payer's budget. The therapy of multiple sclerosis is mainly implemented by the administration of expensive immunomodulatory drugs. The aim of this study is to evaluate the cost-effectiveness of two approaches in the treatment of multiple sclerosis in adult patients, comparing SC glatiramer acetate 40 mg and SC interferon beta-1a 44 μg from the perspective of a healthcare payer. The cost-effectiveness analysis was calculated based on effects identified by multicriteria decision making and direct costs from a healthcare payer perspective. Validation of the results was ensured by one-way sensitivity analysis. For the evaluated intervention SC glatiramer acetate 40 mg, the costs are CZK 176,933 and the effects are 0.24. For SC interferon beta-1a 44 μg, the costs are CZK 175,863 and the effects are 0.76. The resulting ICER was evaluated at -2,229 CZK, suggesting cost ineffectiveness of SC glatiramer acetate 40 mg compared with the comparator SC interferon beta-1a 44 μg.
Czech name
—
Czech description
—

Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Article name in the collection
Advances in Digital Health and Medical Bioengineering, Proceedings of the 11th International Conference on E-Health and Bioengineering, EHB-2023, November 9–10, 2023, Bucharest, Romania – Volume 2: Health Technology Assessment, Biomedical Signal Processing, Medicine and Informatics
ISBN
978-3-031-62519-0
ISSN
1680-0737
e-ISSN
1433-9277
Number of pages
9
Pages from-to
69-77
Publisher name
Springer Nature Switzerland AG
Place of publication
Basel
Event location
Bucuresti
Event date
Nov 9, 2023
Type of event by nationality
WRD - Celosvětová akce
UT code for WoS article
001326809000009

Similar results(10)